Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Center of Chemo- and Bioinformatics, Institute of Biodesign and Complex Systems Modeling, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, The Russian Federation.
J Med Chem. 2023 Jul 13;66(13):8767-8781. doi: 10.1021/acs.jmedchem.3c00397. Epub 2023 Jun 23.
Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine and essential signaling protein associated with inflammation and cancers. One of the newly described roles of MIF is binding to apoptosis-inducing factor (AIF) that "brings" cells to death in pathological conditions. The interaction between MIF and AIF and their nuclear translocation stands as a central event in parthanatos. However, classical competitive MIF tautomerase inhibitors do not interfere with MIF functions in parthanatos. In this study, we employed a pharmacophore-switch to provide allosteric MIF tautomerase inhibitors that interfere with the MIF/AIF co-localization. Synthesis and screening of a focused compound collection around the 1,2,3-triazole core enabled identification of the allosteric tautomerase MIF inhibitor with low micromolar potency (IC = 1.7 ± 0.1 μM). This inhibitor prevented MIF/AIF nuclear translocation and protects cells from parthanatos. These findings indicate that alternative modes to target MIF hold promise to investigate MIF function in parthanatos-mediated diseases.
巨噬细胞移动抑制因子(MIF)是一种多功能细胞因子和必需的信号蛋白,与炎症和癌症有关。MIF 的一个新描述的作用是与凋亡诱导因子(AIF)结合,在病理条件下“将”细胞引向死亡。MIF 和 AIF 之间的相互作用及其核易位是 parthanatos 的核心事件。然而,经典的竞争性 MIF 变构酶抑制剂不会干扰 parthanatos 中的 MIF 功能。在这项研究中,我们采用了药效团切换来提供变构 MIF 变构酶抑制剂,以干扰 MIF/AIF 的共定位。在 1,2,3-三唑核心周围的聚焦化合物集合的合成和筛选,确定了变构 MIF 变构酶抑制剂,其具有低微摩尔效力(IC = 1.7 ± 0.1 μM)。该抑制剂可防止 MIF/AIF 核易位并保护细胞免受 parthanatos 损伤。这些发现表明,针对 MIF 的替代模式有望研究 MIF 在 parthanatos 介导的疾病中的功能。